ENDPOINTS NEWS1h
Af­ter Phase 3 win, Ar­row­head­'s RNAi chas­es Io­n­is to mar­ket en­try in rare ge­net­ic dis­or­der
Arrowhead Pharmaceuticals’ RNAi treatment has succeeded in a registrational test in patients with an ultra-rare lipid ...
ENDPOINTS NEWS2h
Take­da out­lines mid-stage nar­colep­sy da­ta that prompt­ed 'rapid' move in­to Phase 3
Take­da pre­sent­ed fleshed-out Phase 2b da­ta for a nar­colep­sy drug tout­ed by its CEO and re­it­er­at­ed plans to launch ...
ENDPOINTS NEWS3h
Cari­bou says par­tial HLA match­ing will im­prove dura­bil­i­ty of re­sponse to cell ther­a­py
CHICA­GO — Cari­bou’s off-the-shelf cell ther­a­py ap­pears poised to break free from the rapid re­laps­es that have plagued ...
ENDPOINTS NEWS1h
Struc­ture's oral GLP-1 pro­duces com­pa­ra­ble weight loss to Lil­ly's oral can­di­date
Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
ENDPOINTS NEWS1d
In­tel­lia plots Phase 3 study and a 2026 FDA sub­mis­sion af­ter CRISPR ther­a­py cuts swelling at­tacks by 98%
Intellia Therapeutics has revealed that a single infusion of its experimental CRISPR therapy, called NTLA-2002, almost ...
ENDPOINTS NEWS1d
Dai­ichi Sankyo, As­traZeneca say En­her­tu works bet­ter than chemo in cer­tain breast can­cer pa­tients
Daiichi Sankyo and AstraZeneca’s antibody-drug conjugate Enhertu gave HER2-low breast cancer patients a median of 5 more ...
ENDPOINTS NEWS14h
Ex­clu­sive: Iso­tope short­age forces pause of Bris­tol My­ers Phase 3 ra­dio­phar­ma­ceu­ti­cal tri­al
The de­vel­op­ment of the lead drug be­hind Bris­tol My­ers Squibb’s re­cent $4.1 bil­lion ac­qui­si­tion of Rayze­Bio has ...
ENDPOINTS NEWS14h
A small group of melanoma pa­tients may need far less im­munother­a­py with surgery, study sug­gests
In­ter­im re­sults from a clin­i­cal tri­al con­duct­ed by re­searchers in the Nether­lands and Aus­tralia sug­gest that some ...
ENDPOINTS NEWS19h
With a promis­ing new Keytru­da con­tender, Sum­mit pre­pares to spar with Mer­ck
CHICA­GO — Sum­mit Ther­a­peu­tics is pre­pared to take on the world’s best-sell­ing drug. On Thurs­day, the biotech’s stock ...
ENDPOINTS NEWS2d
BMS de­tails con­fir­ma­to­ry tri­al win for KRAS in­hibitor Kraza­ti
Bristol Myers Squibb said its KRAS cancer drug Krazati met the primary endpoint in a Phase 3 confirmatory trial in patients ...
ENDPOINTS NEWS4d
Lil­ly's Retev­mo lands new ac­cel­er­at­ed ap­proval for pe­di­atric can­cers
The FDA on Wednesday granted another accelerated approval to Eli Lilly's cancer drug Retevmo, this time for pediatric ...
ENDPOINTS NEWS2d
No­var­tis sues Mary­land over state law ban­ning lim­its on dis­counts to 340B con­tract phar­ma­cies
Novartis is suing the state of Maryland to block a state law that will ban drugmakers from placing limits on discounts to ...